Xiangxue Pharmaceutical: Legal Opinion of the 2024 First Extraordinary General Meeting of Shareholders
Xiangxue Pharmaceutical: Announcement of Resolutions of the 2024 First Extraordinary General Meeting of Shareholders
Xiangxue Pharmaceutical: Announcement on participating in the 2024 Investor Online Group Reception Day in Guangdong
Xiangxue Pharmaceutical: Notice on Convening the First Extraordinary General Meeting of Shareholders in 2024
Xiangxue Pharmaceuticals: Board of Directors Rules of Procedure
Xiangxue Pharmaceuticals: Rules of Procedure for Shareholders\' Meeting
Xiangxue Pharmaceuticals: Supervisory Board Rules of Procedure
Xiangxue Pharmaceutical: Announcement of Supervisory Committee Resolutions
Xiangxue Pharmaceuticals: Semi-Annual Report 2024
Xiangxue Pharmaceutical: Articles of Association (August 2024)
Xiangxue Pharmaceutical: Announcement on Adjusting the Audit Committee Members of the Board of Directors
Xiangxue Pharmaceuticals: 2024 Semi-Annual Report Summary
Xiangxue Pharmaceutical: Summary table on the use of non-operating capital and other related capital transactions for the first half year of 2024
Xiangxue Pharmaceutical: Announcement of Board Resolutions
Xiangxue Pharmaceutical: Comparative Table of Amendments to the Articles of Association
Xiangxue Pharmaceutical: Announcement regarding abnormal fluctuations in stock trading.
Xiangxue Pharmaceutical: Announcement of abnormal fluctuations in stock trading and serious abnormal fluctuations.
Xiangxue Pharmaceutical: Announcement Regarding Resignation of Securities Affairs Representative
Xiangxue Pharmaceutical: Announcement Regarding Company's Share Price Fluctuation.
Xiangxue Pharmaceutical: Announcement regarding the inclusion of TAEST16001 injection into the list of breakthrough therapy.
No Data
No Data